Drug
Anagliptin clinical trials
Also written SK-0403.
Keep track of what changes. Save the anagliptin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2015 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
JW Pharmaceutical (3) · Kowa Research Institute, Inc. (2) · Institute for Clinical Effectiveness, Japan (1) · Sanwa Kagaku Kenkyusho Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses anagliptin is read from its arms, and is right about nine times in ten.
Testing it · 7
- Glycemic Variability of Combination Therapies in T2DMRecruitingPhase 4JW PharmaceuticalNCT07442006Written as Anagliptin
- Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes TrialCompletedPhase 4Institute for Clinical Effectiveness, JapanNCT02330406Written as Anagliptin
- Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin AloneCompletedPhase 3JW PharmaceuticalNCT01529541Written as Anagliptin
- A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus PatientsCompletedPhase 3JW PharmaceuticalNCT01529528Written as Anagliptin
- A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin TherapyCompletedPhase 2Kowa Research Institute, Inc.NCT01169090Written as SK-0403
- A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403CompletedPhase 1Kowa Research Institute, Inc.NCT01131091Written as SK-0403
- Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes MellitusCompletedPhase 2Sanwa Kagaku Kenkyusho Co., Ltd.NCT00532506Written as SK-0403
Codes
What other systems call anagliptin · ClinicalTrials.gg INT006341
- MeSH (NLM) C583175anagliptinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K726J96838ANAGLIPTINConfirmed FDA, NLM, Wikidata
- Wikidata Q15269682anagliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96202AnagliptinOne source FDA
- DrugBank DB12417One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583175 | anagliptin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K726J96838 | ANAGLIPTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15269682 | anagliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96202 | Anagliptin | One source FDA |
| DrugBank | DB12417 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.